Computational investigation of particle penetration and deposition pattern in a realistic respiratory tract model from different types of Dry Powder Inhalers

Author(s):  
Yun Hwan Kim ◽  
Darson Dezheng Li ◽  
Sena Park ◽  
Dong Seok Yi ◽  
Guan Heng Yeoh ◽  
...  
2018 ◽  
Vol 44 (4-5) ◽  
pp. 211-216 ◽  
Author(s):  
Marian S. Boshra ◽  
Ahmed G. Almeldien ◽  
Randa Salah Eldin ◽  
Ahmed A. Elberry ◽  
Nada Sayed Abdelwahab ◽  
...  

Author(s):  
Richard Pasteka ◽  
Joao Pedro Santos da Costa ◽  
Mathias Forjan

Dry powder inhalers are used by a large number of patients worldwide to treat respiratory diseases. The objective of this work is to experimentally investigate changes in aerosol particle diameter and particle number concentration of pharmaceutical aerosols generated by five dry powder inhalers under realistic inhalation and exhalation conditions. The active respiratory system model (xPULM™) was used as a model of the human respiratory system and to simulate a patient undergoing inhalation therapy. A mechanical upper airway model was developed, manufactured and introduced as a part of the xPULM™ to represent the human upper respiratory tract with high fidelity. Integration of optical aerosol spectrometry technique into the setup allowed for evaluation of pharmaceutical aerosols. The results show that the upper airway model increases the resistance of the overall system and act as a filter for bigger particles (>3 µm). Furthermore, there is a significant difference (p < 0.05) in mean particle diameter between inhaled and exhaled particles with the majority of the particles depositing in the lung. The minimum deposition is reached for particle size of 0.5 µm. The mean particle number concentrations exhaled are 2.94% (BreezHaler®), 2.66% (Diskus®), 10.24% (Ellipta®) 2.13% (HandiHaler®) and 6.22% (Turbohaler®). In conclusion, the xPULM™ active respiratory system model is a viable option for studying interactions of pharmaceutical aerosols and the respiratory tract in terms of applicable deposition mechanisms. The model can support the reduction of animal experimentation in aerosol research and provide an alternative to experiments with human subjects.


Author(s):  
Richard Pasteka ◽  
Lara Schöllbauer ◽  
Joao Pedro Santos da Costa ◽  
Radim Kolar ◽  
Mathias Forjan

Dry powder inhalers are used by a large number of patients worldwide to treat respiratory diseases. The objective of this work is to experimentally investigate changes in aerosol particle diameter and particle number concentration of pharmaceutical aerosols generated by five dry powder inhalers under realistic inhalation and exhalation conditions. The active respiratory system model (xPULM™) was used as a model of the human respiratory system and to simulate a patient undergoing inhalation therapy. A mechanical upper airway model was developed, manufactured and introduced as a part of the xPULM™ to represent the human upper respiratory tract with high fidelity. Integration of optical aerosol spectrometry technique into the setup allowed for evaluation of pharmaceutical aerosols. The results show that the upper airway model increases the resistance of the overall system and act as a filter for bigger particles (>3 µm). Furthermore, there is a significant difference (p < 0.05) in mean particle diameter between inhaled and exhaled particles with the majority of the particles depositing in the lung. The minimum deposition is reached for particle size of 0.5 µm. The mean particle number concentrations exhaled are 2.94% (BreezHaler®), 2.66% (Diskus®), 10.24% (Ellipta®) 2.13% (HandiHaler®) and 6.22% (Turbohaler®). In conclusion, the xPULM™ active respiratory system model is a viable option for studying interactions of pharmaceutical aerosols and the respiratory tract in terms of applicable deposition mechanisms. The model can support the reduction of animal experimentation in aerosol research and provide an alternative to experiments with human subjects.


2020 ◽  
Vol 21 (7) ◽  
Author(s):  
Nermeen A. ElKasabgy ◽  
Islam M. Adel ◽  
Mohamed F. Elmeligy

1994 ◽  
Vol 101 (1-2) ◽  
pp. 1-13 ◽  
Author(s):  
M.P. Timsina ◽  
G.P. Martin ◽  
C. Marriott ◽  
D. Ganderton ◽  
M. Yianneskis

2021 ◽  
Vol 2021 (4) ◽  
pp. 55-63
Author(s):  
O. Katilov

SUBTLETIES OF USING INHALATION DEVICES IN PEDIATRIC PRACTICE O. Katilov National Pirogov Memorial Medical University, Vinnytsya, Ukraine Abstract. Inhalation therapy plays an important role in the treatment of a number of respiratory diseases. Due to the direct delivery of drugs to the respiratory tract, the development of systemic side effects is minimized, which is extremely important for pediatric patients. Today, inhalation therapy is the basic method of treating bronchial asthma. But about 1/3 of patients with bronchoobstructive diseases perform inhalations with serious technical errors. As a result of improper inhalation technique, the drug enters the respiratory tract in insufficient quantities, which leads to poor disease control and frequent exacerbations. Particular difficulties in the use of inhalation devices arise in pediatric practice. Children under 3 years of age are usually unable to perform specific breathing maneuvers. Therefore, for children under 5 years of age, the best choice among delivery devices is metered-dose inhaler (MDI) with a valve spacer. An alternative method of drug delivery is nebulizer therapy. Children older than 5 years can already use dry powder inhalers (DPI). This literature review presents the classification and types of DPI, considers their main technical characteristics, the criteria of the “ideal” delivery device. Based on the literature, it is established that the most optimal inhalation device for children older than 5 years is Easyhaler, which has a number of advantages. It is easy to use. The MDI-like design contributes to the commitment and correct, without technical errors, use of the inhaler. Easyhaler has the appropriate aerodynamic characteristics of the released dose, safe and efficient delivery of the drug. Key words: inhalation therapy, delivery devices, dry powder inhalers, children, bronchial asthma.


2007 ◽  
Vol 40 (23) ◽  
pp. 18
Author(s):  
PATRICE WENDLING

Sign in / Sign up

Export Citation Format

Share Document